Neurol. praxi. 2017;18(5):336-340 | DOI: 10.36290/neu.2019.049

Stevens-Johnson syndrome: complications as part of neurointensive care

MUDr. Irena Doležalová, Ph.D.1, prof. MUDr. Ivan Rektor, CSc.1, 2, prof. MUDr. Milan Brázdil, Ph.D.1, 2
1 Centrum pro epilepsie Brno, 1. neurologická klinika, Fakultní nemocnice u sv. Anny, Brno
2 Středoevropský technologický institut (CEITEC), Brno

Stevens-Johnson syndrome (SJS) is a rare disease with an immunopathological background, most frequently occurring in associationwith a medication administered. The disease is characterized by skin manifestations, specifically maculopapular exanthema, blisters,and large skin defects. Skin signs are accompanied by general ones (temperature, anaemia, leukopenia, hypoalbuminaemia). Themortality is high, with patients most commonly dying from infectious complications. We present a case of a female patient who developedSJS as part of neurointensive care. The aim of this case report is to introduce this rare syndrome to neurological professionals.

Keywords: Stevens-Johnson syndrome, toxic epidermal necrolysis, Lyell’s syndrome, neurointensive care, non-convulsive status
epilepticus.

Received: June 3, 2019; Accepted: June 24, 2019; Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležalová I, Rektor I, Brázdil M. Stevens-Johnson syndrome: complications as part of neurointensive care. Neurol. praxi. 2017;18(5):336-340. doi: 10.36290/neu.2019.049.
Download citation

References

  1. d'Orsi G, Pascarella MG, Martino T, Carapelle E, Pacillo F, Di Claudio MT, Mancini D, Trivisano M, Avolio C, Specchio LM. Intravenous lacosamide in seizure emergencies: Observations from a hospitalized in-patient adult population. Seizure 2016; 42: 20-28. Go to original source... Go to PubMed...
  2. Kuba R. Idiosynkratické nežádoucí účinky antiepileptik a jejich význam. Idiosynkratické nežádoucí účinky antiepileptik a jejich klinický význam. Neurol. praxi 2010; 11: 228-231.
  3. Nešpor D, Lipový B, Gregorová N. Cyklosporin A v terapii toxické epidermální nekrolýzy. Dermatol. praxi 2011; 5: 156-159
  4. Lang N, Lange M, Schmitt FC, Bos M, Weber Y, Evers S, Burghaus L, Kellinghaus C, Schubert-Bast S, Bosel J, Lammers T, Sabolek M, van Baalen A, Dziewas R, Kraft A, Ruf S, Stephani U. Intravenous lacosamide in clinical practice-Results from an independent registry. Seizure 2016; 39: 5-9. Go to original source... Go to PubMed...
  5. Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns 2010; 36: 152-163. Go to original source... Go to PubMed...
  6. Revuz J, Penso D, Roujeau JC, Guillaume JC, Payne CR, Wechsler J, Touraine R. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-1165. Go to original source... Go to PubMed...
  7. Roujeau JC, Guillaume JC, Fabre JP, Penso D, Flechet ML, Girre JP. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126: 37-42. Go to original source... Go to PubMed...
  8. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Ocucati F, Mockenhaupt M, Paoletti C, Shapiro S, Shear N, Schöpf E, Kaufman DW. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-1607. Go to original source... Go to PubMed...
  9. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 1025-1032. Go to original source... Go to PubMed...
  10. Trinka E, Hofler J, Leitinger M, Rohracher A, Kalss G, Brigo F. Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother 2016; 17: 513-534. Go to original source... Go to PubMed...
  11. Uetrecht J, Naisbitt DJ. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013; 65: 779-808. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.